@AnastasiosDimo1
Joined March 2019
  • Tweets3
  • Following67
  • Followers70
NOW we must change the #melanoma management guidelines across the world. #Neoadjuvant #immunotherapy better than adjuvant in resectable stage 3&4 melanoma SWOG1801 HR 0.58 p0.004 fir event-free survial
11
135
449
Very proud of my former fellow, Dr. Rakshit who presented data on hepatotoxicity from sotorasib following IO. Increased rates of grade 3 transaminase elevation if IO<3months from sotorasib #WCLC22
5
Anastasios Dimou retweeted
Karen Reckamp, MD, MS@ReckampK6 Jun 2022
It’s been refreshing to see colleagues and discuss the data at #ASCO2022 We are excited to see coverage #ASCODailyNews of the OS benefit for previously treated NSCLC with ramucirumab and pembrolizumab in S1800A @ASCO dailynews.ascopubs.org/do/10…

Second-Line Pembrolizumab Plus Ramucirumab Extends OS Over Standard of Care in Advanced NSCLC

Findings from the Lung-MAP nonmatched substudy S1800A indicate that second-line pembrolizumab plus ramucirumab demonstrate a potential survival benefit for patients with advanced non–small cell lung...

dailynews.ascopubs.org
1
6
25
Load more